Postoperative decline in <scp>CA</scp> ‐125 as a prognostic biomarker in ovarian cancer: A systematic review and meta‐analysis

Abstract Background Cancer antigen 125 (CA‐125) is widely used for monitoring epithelial ovarian cancer, but the prognostic significance of an early postoperative decline remains uncertain. Objective This systematic review and meta‐analysis evaluated whether postoperative CA‐125 decline is associated with improved survival outcomes. Search Strategy A systematic literature search was conducted to identify studies reporting survival outcomes according to postoperative CA‐125 change following primary cytoreductive surgery. Selection Criteria We included studies investigating the prognostic impact of perioperative or postoperative CA‐125 decline and dynamics in surgically treated patients with ovarian cancer, and correlated CA‐125 changes with survival outcomes. Data Collection and Analysis A total of 12 studies met eligibility criteria for the systematic review. Main Results The primary outcomes were progression‐free survival (PFS) and overall survival (OS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted and pooled using fixed‐ and random‐effects meta‐analysis models. Statistical heterogeneity was assessed using the I 2 statistic and chi‐square test. Of these, three retrospective cohort studies reported sufficient data for quantitative synthesis and were included in the meta‐analysis. Across included studies, postoperative CA‐125 decline was consistently associated with improved survival outcomes. Pooled estimates demonstrated a significant association between postoperative CA‐125 response and prognosis, with moderate heterogeneity observed between studies (I 2 approximately 60%). Conclusions Postoperative CA‐125 decline may represent a clinically significant prognostic marker associated with improved survival outcomes in ovarian cancer patients and may contribute to postoperative risk stratification. Nevertheless, the small number of studies available for quantitative synthesis, together with the considerable methodological heterogeneity among cohorts, warrants cautious interpretation of the findings and underscores the need for larger prospective studies using standardized definitions of CA‐125 response.

Authors

Institutions

Publication Details

Journal
International Journal of Gynecology & Obstetrics
Published
2026-06-19
DOI
https://doi.org/10.1002/ijgo.71146
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Postoperative decline in CA ‐125 as a prognostic biomarker in ovarian cancer: A systematic review and meta‐analysis

Maria Fanaki, Dimitrios Efthimios Vlachos, Dimitrios Haidopoulos, Vasileios Pergialiotis et al.
International Journal of Gynecology & Obstetrics
Ovarian cancer diagnosis and treatment
article

Postoperative decline in CA ‐125 as a prognostic biomarker in ovarian cancer: A systematic review and meta‐analysis

Maria Fanaki, Dimitrios Efthimios Vlachos, Dimitrios Haidopoulos, Vasileios Pergialiotis, Nikolaos Thomakos, Theodora Kordali
article en

Abstract

Abstract Background Cancer antigen 125 (CA‐125) is widely used for monitoring epithelial ovarian cancer, but the prognostic significance of an early postoperative decline remains uncertain. Objective This systematic review and meta‐analysis evaluated whether postoperative CA‐125 decline is associated with improved survival outcomes. Search Strategy A systematic literature search was conducted to identify studies reporting survival outcomes according to postoperative CA‐125 change following primary cytoreductive surgery. Selection Criteria We included studies investigating the prognostic impact of perioperative or postoperative CA‐125 decline and dynamics in surgically treated patients with ovarian cancer, and correlated CA‐125 changes with survival outcomes. Data Collection and Analysis A total of 12 studies met eligibility criteria for the systematic review. Main Results The primary outcomes were progression‐free survival (PFS) and overall survival (OS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted and pooled using fixed‐ and random‐effects meta‐analysis models. Statistical heterogeneity was assessed using the I 2 statistic and chi‐square test. Of these, three retrospective cohort studies reported sufficient data for quantitative synthesis and were included in the meta‐analysis. Across included studies, postoperative CA‐125 decline was consistently associated with improved survival outcomes. Pooled estimates demonstrated a significant association between postoperative CA‐125 response and prognosis, with moderate heterogeneity observed between studies (I 2 approximately 60%). Conclusions Postoperative CA‐125 decline may represent a clinically significant prognostic marker associated with improved survival outcomes in ovarian cancer patients and may contribute to postoperative risk stratification. Nevertheless, the small number of studies available for quantitative synthesis, together with the considerable methodological heterogeneity among cohorts, warrants cautious interpretation of the findings and underscores the need for larger prospective studies using standardized definitions of CA‐125 response.

International Journal of Gynecology & Obstetrics
Alexandra Hospital (GR)
Good health and well-being
Openalex Percentile: Top 7%
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.